EB-DART-NK01 (DLL3/CD56 CAR-NK cells)
Cell therapy
EB-DART-NK01 (DLL3/CD56 CAR-NK cells) is one of 40 biologic programs targeting Small Cell Lung Cancer. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
598 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Lynparza
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Beyfortus
BeiGenePhase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Trodelvy
GileadPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Etopophos
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Company
- BBeijing Biotech